Interim no more: Ashley Magargee to fill Genentech CEO post; Pfizer, Moderna make commercial leadership adjustments

15 Dec 2023
endpts.com
Executive Change
Ashley Magargee will become the CEO of Genentech on Jan. 1, two decades into her tenure at the South San Francisco biotech pioneer, which she joined prior to its $47 billion deal with now-parent Roche.
She’s held the interim post since Nov. 1, when Alexander Hardy left in a surprise move to take the same post at BioMarin. Magargee will report to the CEO of Roche Pharma, Teresa Graham, who herself worked up the corporate ladder of Genentech and Roche on a similar timetable and became the leader of its pharma business in March 2023.
Interim no more: Ashley Magargee to fill Genentech CEO post; Pfizer, Moderna make commercial leadership adjustments
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-
Targets
-
Drugs
-
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.